Recent Posts
Deals•Feb 19, 2026
Altesa Raises $75M for Oral Respiratory Med
Altesa announced a $75 million fundraising round to develop its oral respiratory medication. The capital will support further clinical development and commercialization efforts.
Endpoints News
Deals•Feb 18, 2026
Faeth Goes Public via Merger with Sensei, Raising $200M
Faeth announced its public listing through a merger with Sensei, generating $200 million from a stock sale. The transaction marks Faeth's entry into the public markets.
Endpoints News
Deals•Feb 17, 2026
Six Biotech Companies File for HKEX IPOs
Six biotechnology firms have filed for initial public offerings on the Hong Kong Stock Exchange, signaling a push into Asian capital markets. The filings were announced on February 17, 2026.
Endpoints News
Deals•Feb 13, 2026
Gilead Acquires Global Rights to Genhouse Bio's Oral Cancer Drug for $80M
Gilead announced it will acquire the global rights to an oral cancer drug from China-based biotech Genhouse Bio, paying $80 million upfront. The deal expands Gilead's oncology pipeline as Genhouse prepares for a Hong Kong IPO.
Endpoints News
Deals•Feb 10, 2026
ILiAD Biotechnologies Secures $115M Series B to Advance Whooping Cough Vaccine
ILiAD Biotechnologies announced an oversubscribed $115 million Series B financing on Tuesday. The new capital will fund pivotal Phase 3 trials for its whooping cough vaccine, accelerating development and potential market entry.
Endpoints News
Deals•Feb 10, 2026
Cascade Pharmaceuticals Raises $72M to Develop MASH, Obesity and Diabetes Drugs
Shanghai-based biotech Cascade Pharmaceuticals announced it has secured $72 million (about 500 million yuan) in new funding to advance its pipeline targeting metabolic-associated steatohepatitis (MASH), obesity, and diabetes. The capital will support preclinical and clinical development of its drug candidates.
Endpoints News
Deals•Feb 9, 2026
QuantX Biosciences Secures $85M Series B Funding Led by Lilly and Sanofi Ventures
China‑American biotech QuantX Biosciences announced a $85 million Series B round, led by the venture arms of Eli Lilly and Sanofi. The funding will accelerate its immunology pipeline targeting key immune‑related diseases. The round highlights strong investor interest in biotech innovations.
Endpoints News
Deals•Feb 6, 2026
Agomab Therapeutics and SpyGlass Pharma Set to IPO on Friday
Fibrosis‑focused Agomab Therapeutics and eye‑disease company SpyGlass Pharma announced they will go public on Friday, marking a significant week for biotech IPOs. The offerings are expected to boost the biotech sector's comeback after a slowdown.
Endpoints News
Deals•Feb 5, 2026
Generate:Biomedicines Files for IPO to Commercialize AI-Driven Drugs
Generate:Biomedicines, a Flagship Pioneering-backed AI bio startup, has filed for an initial public offering just nine days after dosing its first patient in a Phase 3 trial. The filing signals the company’s move to raise capital and bring AI-driven drug...
Endpoints News
Deals•Feb 5, 2026
Eikon Therapeutics Announces IPO Amid Valuation Cut
Bay Area biotech startup Eikon Therapeutics is preparing for an initial public offering, shifting from its $1 billion fundraising history. The analysis highlights a significant valuation cut as the company moves toward going public, marking a major event in the biotech...
Endpoints News
Deals•Feb 5, 2026
Veradermics Surges 122% on Debut as Biotech Goes Public
Biotech firm Veradermics, developing an oral form of Rogaine, completed its initial public offering, with its shares jumping 122% on the first day of trading. The strong debut reflects investor enthusiasm for the growing aesthetics market and the company's innovative...
Endpoints News
Deals•Feb 5, 2026
Angitia Biopharma Secures $130M Series D to Advance Musculoskeletal Drug Pipeline
US-China biotech Angitia Biopharmaceuticals announced a $130 million Series D financing to support three biologics in clinical testing for musculoskeletal diseases. The funding will advance its pipeline, including a candidate that previously fell short at Ultragenyx, highlighting investor confidence in...
Endpoints News
Deals•Feb 3, 2026
Menlo Ventures and A16z Back AI Startup Phylo in Undisclosed Funding Round
Menlo Ventures and Andreessen Horowitz (a16z) have invested in Phylo, an AI scientist startup founded by Stanford researchers Le Cong, Yuanhao Qu, Kexin Huang, and Jure Leskovec. The funding round was announced on February 3, 2026, with undisclosed terms.
Endpoints News
News•Jan 29, 2026
Pipeline Cuts for Sanofi; Breakthru Medicine Raises $60M
Sanofi announced a broad portfolio review that will cut several late‑stage drug programs, aiming to streamline its pipeline and improve cost efficiency. The cull affects multiple candidates across therapeutic areas, though specific names were not disclosed. In parallel, Breakthru Medicine...
By Endpoints News
News•Jan 29, 2026
Summit Says FDA Will Decide to Approve Its Cancer Drug by November
Summit Therapeutics announced that the U.S. Food and Drug Administration has set a target date of November 2024 to render a decision on its flagship cancer immunotherapy. The drug, positioned as a next‑generation immuno‑oncology agent, has completed its pivotal Phase III...
By Endpoints News
News•Jan 29, 2026
Agomab Anticipates $182M IPO as It Builds Fibrosis Pipeline
Belgian biotech Agomab Therapeutics announced plans for a Nasdaq IPO targeting roughly $182 million in net proceeds. The company intends to sell about 12.5 million shares, roughly priced near $14.50 each. Proceeds will fund the expansion of its fibrosis pipeline, which includes...
By Endpoints News
News•Jan 29, 2026
Roche Predicts Its Breast Cancer Pill Could Become Its Biggest-Selling Drug
Roche’s oral breast‑cancer therapy is gaining momentum after two positive late‑stage trial readouts demonstrated strong efficacy and tolerable safety. The company has submitted a U.S. FDA filing and expects a decision later this year. An additional pivotal trial will report...
By Endpoints News
News•Jan 29, 2026
Following Abivax, Formation Bio Licenses miR-124 Drug From China
Formation Bio announced a licensing agreement to acquire rights to a miR‑124‑based drug candidate from a Chinese partner, mirroring the target of French biotech Abivax’s recently successful ulcerative colitis therapy. The deal positions Formation Bio to enter the rapidly expanding...
By Endpoints News
News•Jan 29, 2026
Sanofi Says Its €15B Dealmaking Budget, R&D Spend Should Help Ease Looming Dupixent Patent Cliff
Sanofi announced a €14‑15 billion budget for mergers and acquisitions in 2026, alongside a bolstered R&D spend of roughly €7 billion. The pharmaceutical giant aims to counter the looming revenue gap from Dupixent’s patent expiration expected around 2027. Management expects the combined...
By Endpoints News
News•Jan 29, 2026
Tenpoint Gets FDA Nod for Presbyopia Eye Drop and $235M
Tenpoint Therapeutics received FDA approval for its presbyopia eye drop, YUVEZZI, marking the first pharmacologic therapy for age‑related near‑vision loss. A Phase 3 trial demonstrated a statistically significant two‑line improvement in near visual acuity. The company simultaneously announced a $235 million financing...
By Endpoints News
Deals•Jan 29, 2026
Agomab Therapeutics Targets $182M Nasdaq IPO to Fund Fibrosis Pipeline
Belgian biotech Agomab Therapeutics announced plans for a Nasdaq IPO to raise approximately $182 million in net proceeds. The capital will support the development of its fibrosis drug pipeline, with the company aiming to sell 12.5 million shares. The offering...
Endpoints News
Deals•Jan 29, 2026
Premise Health to Merge with Crossover Health to Expand Employer Clinics
Premise Health, an advanced primary care provider, announced a merger with Crossover Health, which runs on‑site health clinics for large employers such as Google and Amazon. The combined company aims to broaden its employer clinic network and help control rising...
Endpoints News
News•Jan 28, 2026
ChenMed CEO Warns Against GLP-1s for Seniors
ChenMed chief executive Chris Chen announced that the senior‑focused primary‑care network will stop encouraging the use of GLP‑1 drugs such as Ozempic and Wegovy for weight‑loss purposes. The decision follows internal data linking these medications to higher rates of dehydration,...
By Endpoints News
News•Jan 28, 2026
Round Three of IRA Negotiations Is Expected to Be ‘Manageable’ for Pharma
Analysts say the third round of Medicare drug‑price negotiations under the Inflation Reduction Act will be largely manageable for large pharmaceutical firms. The round focuses on a limited set of high‑cost specialty medicines, with negotiations slated to begin in 2025....
By Endpoints News
News•Jan 28, 2026
Oral Rogaine Maker Veradermics Looks to Raise $181M From IPO
Veradermics, a biotech developing an oral formulation of minoxidil—the active ingredient in Rogaine—has filed for an initial public offering seeking roughly $181.8 million in net proceeds. The company is in late‑stage clinical testing, reporting efficacy comparable to the established topical product...
By Endpoints News
News•Jan 28, 2026
FDA Asks Court to Pause Louisiana's Abortion Pill Fight
The U.S. Justice Department, representing the Trump administration, has petitioned a federal court to suspend a Louisiana lawsuit challenging the FDA’s approval of the abortion medication mifepristone. The request comes as the FDA conducts a comprehensive safety and efficacy review...
By Endpoints News
News•Jan 28, 2026
Lonza Still Intends to Sell Its Capsules and Health Ingredients Business
Swiss CDMO Lonza reaffirmed its intention to sell its capsules and health ingredients division. The transaction, first announced more than a year ago, has not yet been finalized. Lonza cited ongoing negotiations and market conditions as reasons for the delay....
By Endpoints News
News•Jan 28, 2026
Teva CEO Says It Has Successfully Transitioned Into a Biopharma Company
Teva Pharmaceutical Industries announced that its latest earnings demonstrate a completed shift from a pure‑play generics manufacturer to a biopharma‑focused enterprise. The CEO highlighted that revenue from specialty and branded products now exceeds traditional generic sales, confirming the strategic pivot....
By Endpoints News
News•Jan 28, 2026
HHS Seeks to Protect Drugmakers From Anti-Kickback Laws Ahead of TrumpRx Launch
The U.S. Department of Health and Human Services announced a draft rule that would create a safe‑harbor exemption for drug manufacturers participating in the upcoming TrumpRx platform. The proposal seeks to shield companies from the federal anti‑kickback statute when they...
By Endpoints News
News•Jan 28, 2026
Hengrui Blazes Trail as Chinese Drugmakers Aspire to Go Multinational
Jiangsu Hengrui Pharmaceuticals has surged into the global top‑25 biopharma companies by market value, marking a dramatic shift from its previously low international profile. The Chinese firm leveraged a pipeline of innovative oncology and immunology drugs, securing multiple foreign regulatory...
By Endpoints News
News•Jan 28, 2026
Halozyme Buys Drug Delivery Biotech Surf Bio; Sanofi Backs Sensorion
Halozyme Therapeutics announced a $300 million upfront acquisition of drug‑delivery biotech Surf Bio, adding its PEGylated enzyme platform to Halozyme’s existing portfolio. The deal is expected to broaden Halozyme’s subcutaneous biologics pipeline and accelerate commercialization of next‑generation delivery technologies. Concurrently, Sanofi...
By Endpoints News
News•Jan 28, 2026
Biopharma Sentiment Index | Q1 2026
The Biopharma Sentiment Index (BPSI) jumped to 90 in Q1 2026, up from 78 in the prior quarter, marking the strongest sentiment shift in four years. All ten core measures improved, driven chiefly by a surge in dealmaking and better access...
By Endpoints News
News•Jan 28, 2026
Cellares Raises $257M to Fund Global Expansion as It Eyes 2027 IPO
Cellares, a clinical‑stage cell‑therapy manufacturer, closed a $257 million Series D round to accelerate its global expansion and prepare for a public listing. The funding will support the rollout of new manufacturing sites and scale‑up of its allogeneic cell‑therapy platform. Management has...
By Endpoints News
News•Jan 28, 2026
Lilly Partners with Recombinase-Based Gene Editing Startup Seamless Therapeutics
Eli Lilly has entered a partnership with Seamless Therapeutics, a startup pioneering recombinase‑based gene editing. The collaboration will combine Lilly’s drug development platform with Seamless’s proprietary recombinase enzymes to create precise, permanent DNA modifications for therapeutic applications. Under the agreement,...
By Endpoints News
News•Jan 28, 2026
Boehringer Ingelheim Takes Rare Kidney Disease Drug to Phase 3 Despite Puzzling Mid-Stage Data
Boehringer Ingelheim announced that its experimental oral therapy for a rare kidney disorder will advance to a pivotal Phase 3 trial. The decision follows a Phase 2 study that demonstrated modest improvements in glomerular filtration rate but produced puzzling efficacy signals across...
By Endpoints News
Deals•Jan 28, 2026
Veradermics Targets $181.8M Net Proceeds in Upcoming IPO
Biotech firm Veradermics, developing an oral version of Rogaine, announced plans to go public and raise approximately $181.8 million in net proceeds. The proposed IPO will fund late‑stage testing and commercialization of its hair‑loss treatment.
Endpoints News
Deals•Jan 28, 2026
Cellares Secures $257M Series D Funding to Accelerate Global Expansion and Target 2027 IPO
Clinical-stage cell therapy manufacturer Cellares announced a $257 million Series D funding round to support its global expansion and commercial rollout. The capital will also fund preparations for a planned initial public offering in 2027, highlighting investor confidence in its...
Endpoints News
News•Jan 27, 2026
CMS Picks Lilly’s Trulicity, Gilead's Biktarvy for Third Round of Medicare Negotiations
CMS announced the selection of Eli Lilly’s GLP‑1 diabetes drug Trulicity and Gilead’s HIV therapy Biktarvy for the third round of Medicare drug price negotiations under the Inflation Reduction Act. The program, now in its third cycle, expands the list...
By Endpoints News
News•Jan 27, 2026
Hospitals Could Earn More for Buying US-Made Drugs, CMS Proposes
The Centers for Medicare & Medicaid Services (CMS) has unveiled a proposal to raise hospital reimbursement rates for drugs that are manufactured in the United States. Under the plan, the outpatient prospective payment system would grant higher payments for domestically...
By Endpoints News
News•Jan 27, 2026
Cardiff Execs Depart as Company Drops Mixed Phase 2 Data
Cardiff Oncology (CRDF) saw its shares tumble more than 30% after it released mixed Phase 2 results for its lead oncology candidate. The trial met several secondary endpoints but failed to achieve its primary efficacy goal, prompting uncertainty about the...
By Endpoints News
News•Jan 27, 2026
FDA Lifts Hold on One of Two Phase 3 Gene Editing Studies by Intellia
Intellia Therapeutics received FDA clearance to resume one of its two pivotal Phase 3 gene‑editing trials targeting hereditary transthyretin amyloidosis (hATTR). The agency had placed a partial clinical hold earlier this year over safety concerns, but after additional data the hold...
By Endpoints News
News•Jan 27, 2026
Insilico’s Latest Deal Is a $120M Cardiometabolic Drug Discovery Pact with Qilu Pharma
Insilico Medicine has secured a $120 million drug‑discovery partnership with China’s Qilu Pharma, targeting cardiometabolic diseases. The multi‑year pact follows recent collaborations with Servier and Hygtia Therapeutics, expanding Insilico’s AI platform into new therapeutic areas. Qilu will fund and co‑develop AI‑generated...
By Endpoints News
News•Jan 27, 2026
AstraZeneca Ends Work on Cardio Drug; Lisata and Qilu Terminate Deal
AstraZeneca has terminated its Phase II cardiovascular drug program, pulling the study from the clinical pipeline. The decision coincides with the simultaneous dissolution of a collaboration between biotech Lisata and Chinese partner Qilu, ending a joint development effort. Both moves...
By Endpoints News
News•Jan 27, 2026
Virtual Women’s Health Company Wisp Buys TBD Health
Wisp, a leading women’s tele‑health platform, announced the acquisition of sexual‑health startup TBD Health. The deal expands Wisp’s service catalog to include at‑home STI testing and broader sexual‑health counseling. By integrating TBD Health’s FDA‑cleared diagnostics, Wisp aims to offer a...
By Endpoints News
News•Jan 27, 2026
Boehringer Ingelheim Gets an IBD Bispecific From Shanghai-Based Simcere
Boehringer Ingelheim announced a collaboration with Shanghai‑based Simcere Pharmaceutical to develop a bispecific antibody targeting inflammatory bowel disease (IBD). Boehringer will pay an upfront €42 million, with additional milestone payments tied to development and regulatory progress. The deal gives Boehringer a...
By Endpoints News
News•Jan 27, 2026
FDA Greenlights Life Biosciences' Gene Therapy Study to Rewind the Age of Cells
The U.S. Food and Drug Administration has granted Life Biosciences IND clearance to begin a first‑in‑human gene‑therapy trial aimed at reversing cellular aging. The study will test an epigenetic reprogramming platform that delivers modified mRNA encoding Yamanaka factors to rejuvenate...
By Endpoints News
News•Jan 27, 2026
Roche’s Obesity Shot Posts Decent Weight Loss in Mid-Stage Test, Heads to Phase 3
Roche’s most advanced obesity candidate achieved an average 18.3% weight reduction in a Phase 2 study after nearly a year of treatment. The trial enrolled patients with moderate to severe obesity and demonstrated sustained efficacy without major safety signals. Based on...
By Endpoints News
News•Jan 27, 2026
TRexBio Gets Another $50M to Bring More Treg Candidates Into the Clinic
Bay Area biotech TRexBio announced an additional $50 million extension to its 2024 Series B round. The new capital will be used to advance multiple regulatory T‑cell (Treg) candidates through IND‑enabling studies and early clinical trials. The raise brings the company’s total...
By Endpoints News
Deals•Jan 27, 2026
Boehringer Ingelheim to Acquire IBD Bispecific From Simcere for €42M
German pharma Boehringer Ingelheim has agreed to pay €42 million upfront to Shanghai-based Simcere Pharmaceutical for an IBD bispecific drug candidate, marking a new partnership in immunology.
Endpoints News
Deals•Jan 27, 2026
TRexBio Raises $50M in Series B Extension for Treg Clinical Development
Bay Area biotech TRexBio announced an additional $50 million to its 2024 Series B round, aimed at advancing its pipeline of regulatory T cell (Treg) candidates into clinical trials. The funding will support further development and expansion of its immunotherapy...
Endpoints News
Deals•Jan 27, 2026
Insilico Medicine Secures $120M Drug Discovery Pact with Qilu Pharma
Insilico Medicine announced a $120 million partnership with Chinese pharmaceutical firm Qilu Pharma to develop cardiometabolic therapies. The collaboration will leverage Insilico's AI-driven drug discovery platform to accelerate the identification of novel candidates. The deal highlights growing interest in AI-powered...
Endpoints News
Deals•Jan 27, 2026
Wisp Acquires Sexual Health Startup TBD Health
Virtual women's health platform Wisp announced the acquisition of sexual healthcare startup TBD Health, expanding its tele‑health services. The deal, reported on Jan. 27, 2026, aims to broaden Wisp's offerings in women's sexual health.
Endpoints News
News•Jan 26, 2026
IRA Drug Pricing Petitions Pile up at the Supreme Court
Novartis has become the sixth pharmaceutical company to file an Inflation Reduction Act (IRA) challenge with the U.S. Supreme Court, adding to a growing docket of drug‑pricing disputes. The petitions argue that the IRA’s Medicare price‑negotiation provisions overstep congressional authority...
By Endpoints News
News•Jan 26, 2026
Ex-CytoDyn CEO Sentenced to 30 Months for Pump-and-Dump Scheme
Former CytoDyn CEO Nader Pourhasan received a 30‑month prison sentence after a federal jury found he orchestrated a pump‑and‑dump scheme by falsely promoting a prospective drug candidate. Prosecutors said he inflated the company’s stock by disseminating misleading statements, leading to...
By Endpoints News
News•Jan 26, 2026
Catalent Plans to Close Belgium Cell Therapy Site
Catalent announced it will shut its cell‑therapy manufacturing site in Gosselies, Belgium, citing changing market dynamics and evolving customer needs. The facility, a key European hub for autologous and allogeneic cell‑based products, will cease operations later this year. The decision...
By Endpoints News
News•Jan 26, 2026
Sarepta Touts Three-Year Duchenne Gene Therapy Data After Patient Deaths
Sarepta Therapeutics presented three‑year follow‑up data for its Duchenne muscular dystrophy (DMD) gene therapy, showing that functional gains and dystrophin expression remain durable through 36 months. The long‑term results were released shortly after several trial participants died, prompting renewed safety...
By Endpoints News
News•Jan 26, 2026
Genyro Licences DNA Builder From Caltech; Dizal Targets Hong Kong Listing
Genyro, a San Diego biotech startup, has secured exclusive rights to Caltech’s DNA builder technology, a platform that automates the assembly of long DNA sequences. The system combines high‑throughput enzymatic reactions with error‑correction software, enabling gene circuits and even whole...
By Endpoints News
News•Jan 26, 2026
UK Medicines Agency Seized 20M Illegal Drugs Last Year, Including GLP-1s
Britain’s Medicines and Healthcare products Regulatory Agency (MHRA) reported seizing nearly 20 million doses of illegally traded medicines in 2025, valued at roughly £200 million. The haul included a large share of GLP‑1 agonists, which have surged in demand for obesity and...
By Endpoints News
News•Jan 26, 2026
Genmab Halts Enrollment for Cancer Drug From ProfoundBio Buyout
Genmab announced it has stopped enrolling patients in an early‑stage trial of a cancer candidate acquired from ProfoundBio. The drug was part of Genmab’s $1.8 billion purchase of the US‑China biotech firm. The pause comes shortly after the acquisition closed, raising...
By Endpoints News
News•Jan 24, 2026
First-Movers Respond to Herding; BioMarin Vets Start New Biotech; GSK Buys RAPT Therapeutics; and More
Industry leaders are reacting to a recent wave of investor herding by fast‑tracking biotech launches and strategic deals. BioMarin announced a new venture to spin out a next‑generation gene‑therapy platform, while GSK completed its acquisition of RAPT Therapeutics to bolster...
By Endpoints News
News•Jan 23, 2026
Novo's Wegovy Pill Off to a Solid Start After Just Two Weeks on Market
Novo Nordisk’s oral semaglutide, sold as the Wegovy pill, has demonstrated a strong start within its first three weeks on the U.S. market. Prescription volume has risen sharply, outpacing early forecasts and indicating robust demand for an oral alternative to...
By Endpoints News
News•Jan 23, 2026
EU Kicks Off One-Year Pilot to Expedite Multinational Trials
The European Union has launched a one‑year voluntary pilot to accelerate the start of multinational clinical trials. The initiative introduces a single EU‑wide application that will be reviewed jointly by the European Medicines Agency and national regulators. By streamlining approval...
By Endpoints News
News•Jan 23, 2026
F2G CEO Outlines Biotech's FDA Resubmission Plans, Funding and Expansion
F2G Biotherapeutics will re‑submit its lead antifungal candidate to the FDA after completing Phase 3 enrollment in June. The company has secured a new financing round to fund the filing and scale production. Expansion plans include a U.S. manufacturing site and...
By Endpoints News
News•Jan 23, 2026
Lilly Was the only Pharma Bidder for Ventyx
Eli Lilly emerged as the only pharmaceutical bidder for Ventyx Biosciences, a biotech renowned for its NLRP3 inflammasome programs. The lack of competing offers underscores Ventyx’s niche position in a rapidly expanding therapeutic arena. Lilly’s move signals a strategic push to deepen...
By Endpoints News
News•Jan 23, 2026
Former FDA Deputies Land at Lilly, AbbVie; Italy's Angelini Has a New CEO
Eli Lilly and AbbVie have each hired former FDA deputy officials, with Karin Bok joining Lilly’s regulatory affairs team and an unnamed former FDA deputy moving to AbbVie’s drug‑development unit. The moves follow a broader trend of big pharma recruiting regulators to...
By Endpoints News
News•Jan 22, 2026
High Court Picked Hikma’s ‘Skinny Label’ Fight After Letting the Issue ‘Percolate’
The U.S. Supreme Court has agreed to hear Hikma Pharmaceuticals’ challenge over the use of “skinny labels,” a practice that allows generic manufacturers to market lower‑cost versions of drugs without copying the original brand’s full label. The case follows years...
By Endpoints News
Deals•Jan 22, 2026
BioMarin Veterans Launch New Biotech, Raise $82M for Rare Disease Drug Development
Former BioMarin executives have founded a new biotech focused on rare disease therapeutics. The startup announced an $82 million fundraising round to support development of orphan drugs. The capital will be used to acquire and advance promising rare disease candidates.
Endpoints News
Deals•Jan 22, 2026
Erasca Announces Upsized Public Offering of Common Stock
Erasca announced the pricing of an upsized public offering of its common stock, aiming to raise over $500 million. The offering, part of a broader $500M+ target for several biotech firms, was disclosed in a press release on Jan. 22,...
Endpoints News
Deals•Jan 21, 2026
Claim Health Secures $4.4M Funding to Streamline Home Care Payments
Claim Health, a health‑tech startup, announced a $4.4 million fundraising round to develop AI‑driven solutions that automate payment processes for home‑care providers. The capital will support product development and scaling, with investors not disclosed at the time of the announcement.
Endpoints News
Deals•Jan 20, 2026
Shionogi Acquires Pfizer's Stake in ViiV, Doubling Its Ownership
Pfizer announced it will exit the HIV specialist joint venture ViiV, which it co‑founded with GSK. Shionogi will take over Pfizer’s share, doubling its stake in the company. The move reshapes ViiV’s ownership and strengthens Shionogi’s position in the HIV...
Endpoints News
Deals•Jan 20, 2026
GSK to Acquire RAPT for $2.2B
GlaxoSmithKline (GSK) announced a $2.2 billion acquisition of biotech firm RAPT, securing its food allergy candidate. The deal was unveiled at the JP Morgan Healthcare Conference, marking a major M&A move in the pharma sector.
Endpoints News
Deals•Jan 20, 2026
Exciva Secures $59M Series B Funding to Advance Alzheimer’s Agitation Drug
Exciva announced a €51 million ($59 million) Series B financing round to fund Phase 2 testing of its candidate drug targeting agitation in Alzheimer’s disease. The capital will support clinical development and expand the company's pipeline.
Endpoints News
Deals•Jan 15, 2026
AbbVie Acquires Drug-Device Factory
Pharmaceutical giant AbbVie announced the acquisition of a drug-device manufacturing facility, expanding its presence in the medical device sector. The deal was reported on January 15, 2026, with financial terms undisclosed.
Endpoints News
Deals•Jan 12, 2026
Eli Lilly and Nvidia Sign Five‑year, up to $1 Billion AI Laboratory Deal
Eli Lilly and Nvidia have entered a five‑year partnership valued at up to $1 billion to create an AI laboratory aimed at accelerating drug discovery. The collaboration builds on a prior agreement to build pharma’s largest supercomputer and will leverage Nvidia’s...
Endpoints News
Deals•Jan 9, 2026
Aktis Oncology Lands Biotech's First IPO of 2026, Raising $318M
Aktis Oncology, a radiopharmaceutical startup partnered with Eli Lilly, announced its initial public offering on the Nasdaq, raising $318 million. The IPO marks the first biotech offering of 2026, positioning the company for growth in the radiopharma sector.
Endpoints News
Deals•Jan 9, 2026
Medipost Raises $140M to Expand Korean Stem Cell Therapy to US and Japan
South Korean biotech Medipost announced a $140 million fundraising round to commercialize its allogeneic cell therapy, approved in South Korea since 2012, in the United States and Japan. The capital will support regulatory approvals and market entry in these regions.
Endpoints News
Deals•Jan 8, 2026
Beacon Therapeutics Raises $75M Series C Led by Goldman Sachs Alternatives
Beacon Therapeutics announced a $75 million Series C financing round to advance its vision treatment pipeline. The round was led by Goldman Sachs Alternatives, with participation from a managing partner of the firm’s life sciences team. The funding aims to...
Endpoints News
Deals•Jan 8, 2026
Vizgen Raises $48M in Series E Round to Expand Spatial Biology and Multiomics Tools
Vizgen, a startup developing spatial biology and multiomics mapping technologies, announced a $48 million Series E funding round. The capital will be used to accelerate product development and market expansion. The round underscores continued investor interest in biotech innovation.
Endpoints News
Deals•Jan 8, 2026
French Biotech Enodia Therapeutics Raises €20.7M with Pfizer Backing
Enodia Therapeutics, a French biotech founded in February, announced it has raised €20.7 million (approximately $24 million) to develop protein degrader technology. The financing was aided by pharmaceutical giant Pfizer, marking a significant early-stage corporate investment in the company.
Endpoints News
Deals•Jan 8, 2026
Boltz Secures $28M Seed Funding to Build Open AI Models in Biology
Biotech startup Boltz announced a $28 million seed round to develop open AI models for biology. The funding will support the creation of large language models that predict biomolecular structures, building on advances like AlphaFold. The round highlights growing investor...
Endpoints News
Deals•Jan 8, 2026
Servier Launches €200M Corporate Venture Capital Unit for European Biotech Startups
French pharmaceutical group Servier announced the creation of a corporate venture capital unit focused on European biotech startups, initially funded with about €200 million ($232.9 million). The new VC arm aims to back emerging biotech innovations, joining a wave of large pharma...
Endpoints News
Deals•Jan 8, 2026
Parabilis Medicines Raises $305M to Tackle Undruggable Proteins
Parabilis Medicines announced a $305 million financing round to develop therapies targeting undruggable proteins. The capital will fuel its platform to address challenging protein targets, highlighting strong investor interest in biotech solutions for hard‑to‑drug diseases.
Endpoints News
Deals•Jan 8, 2026
Alveus Therapeutics Raises $159.8M in Series A to Expand Obesity Drug Pipeline
Alveus Therapeutics announced a $159.8 million Series A funding round on Thursday, aiming to accelerate its obesity drug development and challenge market leaders like tirzepatide and semaglutide. The capital will support the company's push into the space dominated by MariTide....
Endpoints News